-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Jv//uPfA7lbVaCGbejbpc09vKV39+rX8M/om1LZvyAB1JlD3vLm1jliwzVMWZinz VT8e/fYQpXwcx7n2O6p6JQ== 0000950142-07-002126.txt : 20070905 0000950142-07-002126.hdr.sgml : 20070905 20070905172207 ACCESSION NUMBER: 0000950142-07-002126 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20070905 DATE AS OF CHANGE: 20070905 GROUP MEMBERS: FRANK H. PEARL GROUP MEMBERS: GEORGE SOROS GROUP MEMBERS: PERSEUS BIOTECH FUND PARTNERS, LLC GROUP MEMBERS: PERSEUS-SOROS BIOPHARMACEUTICAL FUND, L.P. GROUP MEMBERS: PERSEUS-SOROS PARTNERS, LLC GROUP MEMBERS: PERSEUSPUR, L.L.C. GROUP MEMBERS: SFM AH LLC GROUP MEMBERS: SFM PARTICIPATION, L.P. GROUP MEMBERS: SOROS FUND MANAGEMENT LLC SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: AUXILIUM PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001182129 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 233016883 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-79973 FILM NUMBER: 071100638 BUSINESS ADDRESS: STREET 1: 40 VALLEY STREAM PARKWAY CITY: MALVERN STATE: PA ZIP: 19355 BUSINESS PHONE: 484 321 5900 MAIL ADDRESS: STREET 1: 40 VALLEY STREAM PARKWAY CITY: MALVERN STATE: PA ZIP: 19355 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: PERSEUS SOROS BIOPHARMACEUTICAL FUND LP CENTRAL INDEX KEY: 0001111408 IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: ARMY & NAVY CLUB BLDG STREET 2: 1627 I ST NW STE 610 CITY: WASHINGTON STATE: DC ZIP: 20006 BUSINESS PHONE: (212) 651-6389 MAIL ADDRESS: STREET 1: 888 SEVENTH AVE STREET 2: 30TH FL CITY: NEW YORK STATE: NY ZIP: 10106 SC 13D/A 1 sc13da3_auxilium.txt AMENDMENT NO. 3 =============================================================================== UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (AMENDMENT NO. 3) AUXILIUM PHARMACEUTICALS, INC. - -------------------------------------------------------------------------------- (Name of Issuer) COMMON STOCK, PAR VALUE $.01 PER SHARE - -------------------------------------------------------------------------------- (Title of Class of Securities) 05334D107 - -------------------------------------------------------------------------------- (CUSIP Number) ANDREW NICHOLSON PERSEUS-SOROS BIOPHARMACEUTICAL FUND, LP 888 SEVENTH AVENUE, 30TH FLOOR NEW YORK, NY 10106 TEL. NO.: (212) 651-6383 - -------------------------------------------------------------------------------- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) with a copy to JOHN C. KENNEDY, ESQ. PAUL, WEISS, RIFKIND, WHARTON & GARRISON LLP 1285 AVENUE OF THE AMERICAS NEW YORK, NEW YORK 10019-6064 AUGUST 29, 2007 - -------------------------------------------------------------------------------- (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject to this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box [ ]. *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes.) Continued on following pages =============================================================================== CUSIP NO. 05334D107 PAGE 2 OF 15 SCHEDULE 13D - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON Perseus-Soros BioPharmaceutical Fund, LP - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [X] - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS Not applicable - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) [ ] - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OR ORGANIZATION Delaware - -------------------------------------------------------------------------------- 7 SOLE VOTING POWER 1,482,333 (1) NUMBER OF ---------------------------------- SHARES 8 SHARED VOTING POWER BENEFICIALLY 0 OWNED BY ---------------------------------- EACH 9 SOLE DISPOSITIVE POWER REPORTING 1,482,333 (1) PERSON ---------------------------------- WITH 10 SHARED DISPOSITIVE POWER 0 - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,482,333 (1) - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES [X] - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 3.7% (1) - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON PN - -------------------------------------------------------------------------------- - ------------ (1) Includes 304,930 shares of Common Stock issuable upon exercise of warrants. CUSIP NO. 05334D107 PAGE 3 OF 15 SCHEDULE 13D - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON Perseus-Soros Partners, LLC - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [X] - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS Not Applicable - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) [ ] - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OR ORGANIZATION Delaware - -------------------------------------------------------------------------------- 7 SOLE VOTING POWER 1,482,333 (1) NUMBER OF ---------------------------------- SHARES 8 SHARED VOTING POWER BENEFICIALLY 0 OWNED BY ---------------------------------- EACH 9 SOLE DISPOSITIVE POWER REPORTING 1,482,333 (1) PERSON ---------------------------------- WITH 10 SHARED DISPOSITIVE POWER 0 - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,482,333 (1) - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES [X] - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 3.7% (1) - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON OO - -------------------------------------------------------------------------------- - ------------ (1) Includes 304,930 shares of Common Stock issuable upon exercise of warrants. CUSIP NO. 05334D107 PAGE 4 OF 15 SCHEDULE 13D - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON Perseus BioTech Fund Partners, LLC - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [X] - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS Not Applicable - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) [ ] - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OR ORGANIZATION Delaware - -------------------------------------------------------------------------------- 7 SOLE VOTING POWER 0 NUMBER OF ---------------------------------- SHARES 8 SHARED VOTING POWER BENEFICIALLY 1,482,333 (1) OWNED BY ---------------------------------- EACH 9 SOLE DISPOSITIVE POWER REPORTING 0 PERSON ---------------------------------- WITH 10 SHARED DISPOSITIVE POWER 1,482,333 (1) - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,482,333 (1) - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES [X] - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 3.7% (1) - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON OO - -------------------------------------------------------------------------------- - ------------ (1) Includes 304,930 shares of Common Stock issuable upon exercise of warrants. CUSIP NO. 05334D107 PAGE 5 OF 15 SCHEDULE 13D - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON SFM Participation, L.P. - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [X] - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS Not Applicable - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) [ ] - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OR ORGANIZATION Delaware - -------------------------------------------------------------------------------- 7 SOLE VOTING POWER 0 NUMBER OF ---------------------------------- SHARES 8 SHARED VOTING POWER BENEFICIALLY 1,482,333 (1) OWNED BY ---------------------------------- EACH 9 SOLE DISPOSITIVE POWER REPORTING 0 PERSON ---------------------------------- WITH 10 SHARED DISPOSITIVE POWER 1,482,333 (1) - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,482,333 (1) - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES [X] - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 3.7% (1) - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON PN - -------------------------------------------------------------------------------- - ------------ (1) Includes 304,930 shares of Common Stock issuable upon exercise of warrants. CUSIP NO. 05334D107 PAGE 6 OF 15 SCHEDULE 13D - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON SFM AH LLC - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [X] - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS Not Applicable - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) [ ] - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OR ORGANIZATION Delaware - -------------------------------------------------------------------------------- 7 SOLE VOTING POWER 0 NUMBER OF ---------------------------------- SHARES 8 SHARED VOTING POWER BENEFICIALLY 1,482,333 (1) OWNED BY ---------------------------------- EACH 9 SOLE DISPOSITIVE POWER REPORTING 0 PERSON ---------------------------------- WITH 10 SHARED DISPOSITIVE POWER 1,482,333 (1) - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,482,333 (1) - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES [X] - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 3.7% (1) - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON OO - -------------------------------------------------------------------------------- - ------------ (1) Includes 304,930 shares of Common Stock issuable upon exercise of warrants. CUSIP NO. 05334D107 PAGE 7 OF 15 SCHEDULE 13D - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON Frank H. Pearl (in the capacity described herein) - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [X] - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS Not Applicable - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) [_] - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OR ORGANIZATION United States - -------------------------------------------------------------------------------- 7 SOLE VOTING POWER 0 NUMBER OF ---------------------------------- SHARES 8 SHARED VOTING POWER BENEFICIALLY 1,527,333 (1) OWNED BY ---------------------------------- EACH 9 SOLE DISPOSITIVE POWER REPORTING 0 PERSON ---------------------------------- WITH 10 SHARED DISPOSITIVE POWER 1,527,333 (1) - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,527,333 (1) - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES [ ] - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 3.8% (1) - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON IN - -------------------------------------------------------------------------------- - ------------ (1) Includes 304,930 shares of Common Stock issuable upon exercise of warrants and 45,000 shares of Common Stock issuable upon the exercise of options. CUSIP NO. 05334D107 PAGE 8 OF 15 SCHEDULE 13D - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON George Soros (in the capacity described herein) - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [X] - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS Not Applicable - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) [ ] - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OR ORGANIZATION United States - -------------------------------------------------------------------------------- 7 SOLE VOTING POWER 0 NUMBER OF --------------------------------- SHARES 8 SHARED VOTING POWER BENEFICIALLY 1,527,333 (1) OWNED BY --------------------------------- EACH 9 SOLE DISPOSITIVE POWER REPORTING 0 PERSON --------------------------------- WITH 10 SHARED DISPOSITIVE POWER 1,527,333 (1) - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,527,333 (1) - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES [ ] - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 3.8% (1) - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON IA - -------------------------------------------------------------------------------- - ------------ (1) Includes 304,930 shares of Common Stock issuable upon exercise of warrants and 45,000 shares of Common Stock issuable upon the exercise of options. CUSIP NO. 05334D107 PAGE 9 OF 15 SCHEDULE 13D - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON Soros Fund Management LLC - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [X] - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS Not Applicable - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) [ ] - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OR ORGANIZATION Delaware - -------------------------------------------------------------------------------- 7 SOLE VOTING POWER 0 NUMBER OF -------------------------------- SHARES 8 SHARED VOTING POWER BENEFICIALLY 1,527,333 (1) OWNED BY -------------------------------- EACH 9 SOLE DISPOSITIVE POWER REPORTING 0 PERSON -------------------------------- WITH 10 SHARED DISPOSITIVE POWER 1,527,333 (1) - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,527,333 (1) - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES [ ] - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 3.8% (1) - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON OO; IA - -------------------------------------------------------------------------------- - ------------ (1) Includes 304,930 shares of Common Stock issuable upon exercise of warrants and 45,000 shares of Common Stock issuable upon the exercise of options. CUSIP NO. 05334D107 PAGE 10 OF 15 SCHEDULE 13D - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON Perseuspur, L.L.C. - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [X] - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS Not Applicable - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) [ ] - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OR ORGANIZATION Delaware - -------------------------------------------------------------------------------- 7 SOLE VOTING POWER 0 NUMBER OF ---------------------------------- SHARES 8 SHARED VOTING POWER BENEFICIALLY 1,482,333 (1) OWNED BY ---------------------------------- EACH 9 SOLE DISPOSITIVE POWER REPORTING 0 PERSON ---------------------------------- WITH 10 SHARED DISPOSITIVE POWER 1,482,333 (1) - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,482,333 (1) - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES [X] - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 3.7% (1) - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON OO - -------------------------------------------------------------------------------- - ------------ (1) Includes 304,930 shares of Common Stock issuable upon exercise of warrants. CUSIP NO. 05334D107 PAGE 11 OF 15 Pursuant to Rule 13d-2(a) of Regulation 13D-G of the General Rules and Regulations under the Securities Exchange Act of 1934, as amended (the "Act"), the undersigned hereby amend their Schedule 13D Statement dated July 28, 2004, as amended by Amendment No. 1 filed on July 7, 2005 and Amendment No. 2 filed on December 11, 2006 (as amended, the "Schedule 13D") relating to the common stock, par value $.01 per share (the "Common Stock"), of Auxilium Pharmaceuticals, Inc., a Delaware corporation (the "Company"). Item 1. SECURITY AND ISSUER. No material change. Item 2. IDENTITY AND BACKGROUND. (d) and (e) The first paragraph of these sections is hereby amended and restated as follows: On December 27, 2002, George Soros appealed a decision of the 11e Chambre du Tribunal Correctionnel in Paris, France that fined him 2.2 million euros on December 20, 2002 based on a finding of insider trading with respect to trading in securities of Societe Generale in 1988. On March 24, 2005, the Paris Court of Appeal affirmed the decision of the 11e Chambre du Tribunal Correctionnel and on June 14, 2006 the Cour de Cassation upheld such decision, but ordered the Court of Appeal to determine whether the fine should be reduced. On December 13, 2006, George Soros appealed the decision to the European Court of Human Rights. On March 20, 2007, the Paris Court of Appeal reduced the fine imposed against George Soros from 2.2 million euros to 940,000 euros. Item 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION. No material change. Item 4. PURPOSE OF TRANSACTION. Item 4 is hereby amended by adding the following: "On August 29, 2007, the Purchaser sold 1,000,000 shares of the Company's Common Stock at a price of $18.90 per share in a Rule 144 transaction. "In addition, information concerning other transactions in the shares of Common Stock effected by the Reporting Persons during the past 60 days is set forth in Schedule A hereto and is incorporated herein by reference. All of such transactions were effected in open market sales in Rule 144 transactions." CUSIP NO. 05334D107 PAGE 12 OF 15 Item 5. INTEREST IN SECURITIES OF THE ISSUER. (a) Item 5(a) is hereby amended and restated in its entirety as follows: "(a) As set forth above, the Purchaser beneficially owns 1,177,403 shares of Common Stock and warrants to purchase an aggregate of 304,930 shares of Common Stock. Each of the New Warrants and the 2005 Warrants are exercisable at any time until their expiration date. Accordingly, as of the date hereof and assuming the exercise of the warrants, each of the Reporting Persons, except SFM LLC, Mr. Soros and Mr. Pearl, may be deemed to beneficially own an aggregate of 1,482,333 shares of Common Stock. Based on calculations made in accordance with Rule 13d-3(d) and based on information provided by the Company in its Registration Statement on Form S-3 filed on August 27, 2007 indicating that there were 40,048,800 shares of Common Stock outstanding as of August 21, 2007, this represents approximately 3.7% of the outstanding shares of Common Stock. As of the date hereof, Options to purchase 45,000 shares of Common Stock have vested or will vest within 60 days. Accordingly, as of the date hereof and assuming the exercise of the warrants and the Options, SFM LLC, Mr. Soros and Mr. Pearl each may be deemed to beneficially own an aggregate of 1,527,333 shares of Common Stock. Based on the above calculations and information, this represents approximately 3.8% of the outstanding shares of Common Stock." (b) Item 5(b) is hereby amended and restated in its entirety as follows: "(i) Each of the Purchaser and Perseus-Soros Partners may be deemed to have sole power to direct the voting and disposition of the 1,482,333 shares of Common Stock beneficially owned by the Purchaser (assumes the exercise of the warrants held for the account of the Purchaser). (ii) By virtue of the relationships between and among the Reporting Persons described in Item 2 of this Schedule 13D, each of the Reporting Persons, other than the Purchaser and Perseus-Soros Partners may be deemed to share the power to direct the voting and disposition of the 1,482,333 shares of Common Stock beneficially owned by the Purchaser (assumes the exercise of the warrants held for the account of the Purchaser). (iii) By virtue of the relationships between and among the Reporting Persons described in Item 2 of this Schedule 13D, each of SFM LLC, Mr. Soros and Mr. Pearl may be deemed to share the power to direct the voting and disposition of the 45,000 shares of Common Stock issuable upon exercise of Options that have vested on or within 60 days of the date hereof." CUSIP NO. 05334D107 PAGE 13 OF 15 (c) Item 5(c) is hereby amended by adding the following: "On August 29, 2007, the Purchaser sold 1,000,000 shares of the Company's Common Stock at a price of $18.90 per share in a Rule 144 transaction. "In addition, information concerning other transactions in the shares of Common Stock effected by the Reporting Persons during the past 60 days is set forth in Schedule A hereto and is incorporated herein by reference. All of such transactions were effected in open market sales in Rule 144 transactions." (d) No material change. (e) As of August 29, 2007, the Reporting Persons ceased to be the beneficial owners of more than five percent of the shares of the Common Stock of the Company. Item 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER. No material change. Item 7. MATERIAL TO BE FILED AS EXHIBITS. Exhibit 1: Joint Filing Agreement, dated December 7, 2006, among (i) Perseus-Soros BioPharmaceutical Fund, LP, (ii) Perseus-Soros Partners, LLC, (iii) Perseus BioTech Fund Partners, LLC, (iv) SFM Participation, L.P., (v) SFM AH LLC, (vi) Frank H. Pearl, (vii) George Soros, (viii) Soros Fund Management LLC and (ix) Perseuspur, LLC. (previously filed) Exhibit 2: Power of Attorney, dated May 9, 2007, appointing Kenneth M. Socha and Rona Kennedy as Attorney-in-Fact for Frank H. Pearl. (previously filed) Exhibit 3: Power of Attorney, dated June 16, 2005, appointing Armando T. Belly, Jodye Anzalotta, Maryann Canfield, Jay Schoenfarber and Robert Soros as Attorney-in-Fact for George Soros. (previously filed) CUSIP NO. 05334D107 PAGE 14 OF 15 SIGNATURE After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct. Dated: September 5, 2007 PERSEUS-SOROS BIOPHARMACEUTICAL FUND, LP By: Perseus-Soros Partners, LLC, General Partner By: SFM Participation, L.P., Managing Member By: SFM AH LLC General Partner By: Soros Fund Management LLC, Managing Member By: /s/ Jodye Anzalotta ---------------------------------------- Name: Jodye Anzalotta Title: Assistant General Counsel PERSEUS-SOROS PARTNERS, LLC By: SFM Participation, L.P. Managing Member By: SFM AH LLC General Partner By: Soros Fund Management LLC, Managing Member By: /s/ Jodye Anzalotta ---------------------------------------- Name: Jodye Anzalotta Title: Assistant General Counsel PERSEUS BIOTECH FUND PARTNERS, LLC By: Perseuspur, L.L.C. Managing Member By: /s/ Kenneth M. Socha ---------------------------------------- Name: Kenneth M. Socha Title: Senior Managing Director PERSEUSPUR, L.L.C. By: /s/ Kenneth M. Socha ---------------------------------------- Name: Kenneth M. Socha Title: Senior Managing Director CUSIP NO. 05334D107 PAGE 15 OF 15 MR. FRANK H. PEARL By: /s/ Kenneth M. Socha ---------------------------------------- Name: Kenneth M. Socha Title: Attorney-in-Fact SFM PARTICIPATION, L.P. By: SFM AH LLC General Partner By: Soros Fund Management LLC, Managing Member By: /s/ Jodye Anzalotta ---------------------------------------- Name: Jodye Anzalotta Title: Assistant General Counsel SFM AH LLC By: Soros Fund Management LLC, Managing Member By: /s/ Jodye Anzalotta ---------------------------------------- Name: Jodye Anzalotta Title: Assistant General Counsel MR. GEORGE SOROS By: /s/ Jodye Anzalotta ---------------------------------------- Name: Jodye Anzalotta Title: Attorney-in-Fact SOROS FUND MANAGEMENT LLC By: /s/ Jodye Anzalotta ---------------------------------------- Name: Jodye Anzalotta Title: Assistant General Counsel SCHEDULE A QUANTITY TRADE PRICE PER TRANSACTION ENTITY SOLD DATE SHARE Perseus-Soros BioPharmaceutical Fund, LP 900 8/30/2007 $19.75 Perseus-Soros BioPharmaceutical Fund, LP 100 8/30/2007 $19.76 Perseus-Soros BioPharmaceutical Fund, LP 1,000 8/30/2007 $19.82 Perseus-Soros BioPharmaceutical Fund, LP 500 8/30/2007 $19.89 Perseus-Soros BioPharmaceutical Fund, LP 700 8/30/2007 $19.95 Perseus-Soros BioPharmaceutical Fund, LP 200 8/31/2007 $19.81 Perseus-Soros BioPharmaceutical Fund, LP 100 8/31/2007 $19.83 Perseus-Soros BioPharmaceutical Fund, LP 1,115 8/31/2007 $19.85 Perseus-Soros BioPharmaceutical Fund, LP 13,064 9/4/2007 $19.75 Perseus-Soros BioPharmaceutical Fund, LP 313 9/4/2007 $19.76 Perseus-Soros BioPharmaceutical Fund, LP 3,248 9/4/2007 $19.78 Perseus-Soros BioPharmaceutical Fund, LP 7,520 9/4/2007 $19.79 Perseus-Soros BioPharmaceutical Fund, LP 2,531 9/4/2007 $19.80 Perseus-Soros BioPharmaceutical Fund, LP 11,000 9/4/2007 $19.81 Perseus-Soros BioPharmaceutical Fund, LP 7,500 9/4/2007 $19.82 Perseus-Soros BioPharmaceutical Fund, LP 3,798 9/4/2007 $19.83 Perseus-Soros BioPharmaceutical Fund, LP 2,295 9/4/2007 $19.84 Perseus-Soros BioPharmaceutical Fund, LP 1,957 9/4/2007 $19.85 Perseus-Soros BioPharmaceutical Fund, LP 484 9/4/2007 $19.86 Perseus-Soros BioPharmaceutical Fund, LP 200 9/4/2007 $19.87 Perseus-Soros BioPharmaceutical Fund, LP 458 9/4/2007 $19.90 Perseus-Soros BioPharmaceutical Fund, LP 6,878 9/5/2007 $19.79 Perseus-Soros BioPharmaceutical Fund, LP 549 9/5/2007 $19.80 Perseus-Soros BioPharmaceutical Fund, LP 2,573 9/5/2007 $19.81 Perseus-Soros BioPharmaceutical Fund, LP 800 9/5/2007 $19.84 Perseus-Soros BioPharmaceutical Fund, LP 118 9/5/2007 $19.85 Perseus-Soros BioPharmaceutical Fund, LP 2,582 9/5/2007 $19.86 Perseus-Soros BioPharmaceutical Fund, LP 3,000 9/5/2007 $19.87 Perseus-Soros BioPharmaceutical Fund, LP 7,025 9/5/2007 $19.88 Perseus-Soros BioPharmaceutical Fund, LP 4,875 9/5/2007 $19.89 Perseus-Soros BioPharmaceutical Fund, LP 300 9/5/2007 $19.90 Perseus-Soros BioPharmaceutical Fund, LP 1,469 9/5/2007 $19.91 Perseus-Soros BioPharmaceutical Fund, LP 400 9/5/2007 $19.92 Perseus-Soros BioPharmaceutical Fund, LP 1,300 9/5/2007 $19.93 Perseus-Soros BioPharmaceutical Fund, LP 775 9/5/2007 $19.94 Perseus-Soros BioPharmaceutical Fund, LP 1,150 9/5/2007 $19.95 Perseus-Soros BioPharmaceutical Fund, LP 3,400 9/5/2007 $19.96 Perseus-Soros BioPharmaceutical Fund, LP 1,693 9/5/2007 $19.97 Perseus-Soros BioPharmaceutical Fund, LP 4,473 9/5/2007 $19.98 Perseus-Soros BioPharmaceutical Fund, LP 5,500 9/5/2007 $19.99 Perseus-Soros BioPharmaceutical Fund, LP 14,865 9/5/2007 $20.00 Perseus-Soros BioPharmaceutical Fund, LP 3,662 9/5/2007 $20.01 Perseus-Soros BioPharmaceutical Fund, LP 2,412 9/5/2007 $20.02 Perseus-Soros BioPharmaceutical Fund, LP 10,844 9/5/2007 $20.03 Perseus-Soros BioPharmaceutical Fund, LP 6,521 9/5/2007 $20.04 Perseus-Soros BioPharmaceutical Fund, LP 14,098 9/5/2007 $20.05 Perseus-Soros BioPharmaceutical Fund, LP 2,700 9/5/2007 $20.06 Perseus-Soros BioPharmaceutical Fund, LP 2,660 9/5/2007 $20.07 Perseus-Soros BioPharmaceutical Fund, LP 4,024 9/5/2007 $20.08 Perseus-Soros BioPharmaceutical Fund, LP 1,400 9/5/2007 $20.09 Perseus-Soros BioPharmaceutical Fund, LP 11,231 9/5/2007 $20.10 Perseus-Soros BioPharmaceutical Fund, LP 1,500 9/5/2007 $20.11 Perseus-Soros BioPharmaceutical Fund, LP 1,900 9/5/2007 $20.12 Perseus-Soros BioPharmaceutical Fund, LP 2,800 9/5/2007 $20.13 Perseus-Soros BioPharmaceutical Fund, LP 5,538 9/5/2007 $20.15 Perseus-Soros BioPharmaceutical Fund, LP 2,700 9/5/2007 $20.16 Perseus-Soros BioPharmaceutical Fund, LP 600 9/5/2007 $20.19 Perseus-Soros BioPharmaceutical Fund, LP 502 9/5/2007 $20.20 Perseus-Soros BioPharmaceutical Fund, LP 2,200 9/5/2007 $20.22 -----END PRIVACY-ENHANCED MESSAGE-----